CLOs on the Move

Richman Root Delaney MD

www.richmanrootdelaney.com

 
Richman Root Delaney MD is a Waterford, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Medical Marijuana Incorporated

We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company`s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.`s headquarters is in San Diego, California.

City of Melbourne FL

Terms Of Use Please be aware that when engaging with the City of Melbourne, Florida, through its social media pages, you are agreeing to the following terms of use: 1.) The Citys social media sites are not monitored at all times. Do NOT use thes...

Stand Firm Fitness Your Prsnl

Stand Firm Fitness Your Prsnl is a Wilton, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MediStar Billing Center

MediStar Billing Center is a Trumbull, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T3D Therapeutics

T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.